Left Ventricular Dysfunction

A machine learning network, a form of artificial intelligence, was able to consistently measure left ventricular ejection fraction as well as LV mass in cardiac MRI scans faster, with comparable reliability to experienced clinicians and a significantly shorter training period.

PARIS — Sacubitril/valsartan was associated with improvements in cardiac structure and function as well as N-terminal pro-B natriuretic peptide in patients with HF with reduced ejection fraction, according to the PROVE-HF and EVALUATE-HF studies presented at the European Society of Cardiology Congress.

The FDA has established a pathway to marketing for Revascor, an investigational cell therapy used for the prevention of postimplantation mucosal bleeding in patients with end-stage chronic heart failure who require a left ventricular assist device.

The FDA has approved the Barostim Neo System for the improvement of symptoms in patients with advanced HF who are not suited for treatment with other HF devices, such as cardiac resynchronization therapy. The FDA gave the device a Breakthrough Device designation, according to an agency press release.